Neumora Therapeutics Accounts Payable

Neumora Therapeutics (NMRA) currently reports a accounts payable of $4.1M as of June 2026. That compares with $640K in the prior-year period — up 543.9% year over year. Use the charts on this page to explore Neumora Therapeutics's accounts payable history and peer comparisons.

Neumora Therapeutics's accounts payable increased from $640K to $4.1M — a 543.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Neumora Therapeutics reported $4.1M in accounts payable as of June 2026. That compares with $640K in the prior-year period — up 543.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $4.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Neumora Therapeutics, and consider following NMRA for alerts when major investors trade the stock.